Anaplastic Astrocytoma Treatment Market Forecast 2016-21

Anaplastic astrocytoma is a malignant brain tumor that is extremely rare. Astrocytomas are tumors that grow from astrocytes, which are star-shaped brain cells. Based on the pace of cell reproduction and their potential to spread over neighboring tissues, the disease has been divided into four groups: Grade I, Grade II, Grade III, and Grade IV. Low-grade astrocytomas include Grade I and Grade II astrocytomas, which are non-malignant. Grade III and Grade IV astrocytomas, on the other hand, are malignant and are referred to as high grade astrocytomas. Lower-grade astrocytomas can progress to high-grade astrocytomas over time. Grade III astrocytomas, on the other hand, are also known as anaplastic astrocytomas.

Global Anaplastic Astrocytoma Treatment Market Dynamics

The global anaplastic astrocytoma treatment market is predicted to increase due to an increasing number of medication candidates in the pipeline that may get regulatory approval throughout the forecast period. The only medicine approved by the US FDA for Anaplastic Astrocytoma is temozolomide (Temodar).Temodar is an alkylating agent that has been approved for both newly diagnosed and refractory anaplastic astrocytoma patients who have seen their disease develop after taking nitrosourea and procarbazine-containing drugs. For the treatment of anaplastic astrocytoma, however, several products are in development. For example, Decipher Pharmaceuticals, Inc. is now conducting Phase 1 clinical studies for DCC-2618, a therapeutic candidate. In September 2017, the medicine was designated as an orphan medication for the treatment of anaplastic astrocytoma and glioblastoma multiforme (GBM) An investigational medicine called PAC-1 was approved for a clinical trial in people with anaplastic astrocytoma in November 2017. The drug candidate is being developed by Vanquish Oncology, Inc. The goal of the study is to assess if the medication candidate is safe to use in combination with temozolomide, a common chemotherapy medicine.

Global Anaplastic Astrocytoma Treatment Market – Regional Outlook

Because of increased awareness of rare disorders such as anaplastic astrocytoma and the existence of top clinical-stage firms in the region, North America is likely to account for a significant share of the worldwide anaplastic astrocytoma treatment market. For example, antineoplaston therapy (atengenal + astuge) is being tested in a study sponsored by Burzynski Research Institute in Texas, United States. Phase 2 clinical trials are under underway for the investigation. Furthermore, Erlotinib is being tested for anaplastic astrocytoma in a clinical trial sponsored by Northwell Health in partnership with Genentech, Inc. (a Roche AG subsidiary). Phase 1 of the research is now underway.. Approval of these pipeline products over the forecast period would boost growth of North America anaplastic astrocytoma treatment market.

Furthermore, the approval of generic temozolomide will be critical in promoting medicine use, particularly in growing economies such as Asia Pacific and Latin America. Amerigen Pharmaceuticals Limited's generic version of Temodar was approved by the FDA in 2016. Jiangsu Province, China, is home to the company's main facility. In July 2016, the top global generic players, including Mylan N.V., were granted permission for a generic version of Temodar. The introduction of generic medications is likely to boost the anaplastic astrocytoma treatment market.